Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guilford restarts Aquavan clinical program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Revised clinical development strategy for Guilford's Phase III Aquavan (propofol prodrug) procedural sedative agreed to by FDA will include two pivotal trials - one in colonoscopy and the other in minor surgical procedures, the firm says. A prerequisite dose-ranging study in colonoscopy is planned. Guilford suspended Phase III trial enrollment in April after an interim analysis indicated that doses to date have been too high, pushing back NDA filing plans to the second-half of 2006 (1Pharmaceutical Approvals Monthly April 2005, p. 13). Under the revised strategy, Guilford will "immediately" re-initiate previously planned studies for ICU sedation and potential drug interactions, the firm says...

You may also be interested in...

Aquavan NDA Delayed While Guilford Adjusts Dosing In Phase III Study

Guilford's suspension of Aquavan Phase III trial enrollment to recalculate dosing levels will delay an NDA filing until the second half of 2006, the firm says

Amwell Stock Rises 28% In Market Debut

Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.

Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents

Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts